EAM
APTO

Evanson Asset Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Evanson Asset Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-88
Closed -$25.3K – 288
2023
Q1 		$25.3K Hold
88
– – ﹤0.01% 269
2022
Q4 		$22.9K Buy
+88
New +$23.6K ﹤0.01% 267

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Evanson Asset Management's APTO Position: Q2 2023 in Review

Evanson Asset Management sold out of Aptose Biosciences, Inc. (APTO) in Q2 2023, closing a stake of 88 shares — an estimated $25.3K sold.

Evanson Asset Management first reported a position in APTO in Q4 2022 and held it in 2 quarters. The position peaked at $25.3K in Q1 2023. 24 funds tracked by Wall St. Rank hold APTO as of Q2 2023.

  • Evanson Asset Management reported no remaining Aptose Biosciences, Inc. position as of Q2 2023 after selling out during the quarter.
  • Evanson Asset Management sold 88 Aptose Biosciences, Inc. shares in Q2 2023, an estimated $25.3K.
  • Evanson Asset Management first reported a position in Aptose Biosciences, Inc. in Q4 2022 and held it in 2 quarters.
  • Evanson Asset Management's Aptose Biosciences, Inc. position peaked at $25.3K in Q1 2023.
  • 24 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2023.

Based on Evanson Asset Management's 13F filing for Q2 2023, filed 11 Jul 2023.